newsfilter
← Latest News
GlobeNewswire·

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

LITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity